- Home
- NXT vs EXAS Comparison
NXT vs EXAS Comparison
Compare NXT & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXT
- EXAS
- Stock Information
- Founded
- NXT 2013
- EXAS 1995
- Country
- NXT United States
- EXAS United States
- Employees
- NXT N/A
- EXAS N/A
- Industry
- NXT Semiconductors
- EXAS Medical Specialities
- Sector
- NXT Technology
- EXAS Health Care
- Exchange
- NXT Nasdaq
- EXAS Nasdaq
- Market Cap
- NXT 8.8B
- EXAS 10.2B
- IPO Year
- NXT 2023
- EXAS N/A
- Fundamental
- Price
- NXT $66.70
- EXAS $53.94
- Analyst Decision
- NXT Buy
- EXAS Strong Buy
- Analyst Count
- NXT 18
- EXAS 22
- Target Price
- NXT $63.44
- EXAS $67.38
- AVG Volume (30 Days)
- NXT 2.4M
- EXAS 2.9M
- Earning Date
- NXT 10-29-2025
- EXAS 11-04-2025
- Dividend Yield
- NXT N/A
- EXAS N/A
- EPS Growth
- NXT N/A
- EXAS N/A
- EPS
- NXT 3.67
- EXAS N/A
- Revenue
- NXT $3,103,529,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- NXT $15.20
- EXAS $16.50
- Revenue Next Year
- NXT $9.53
- EXAS $12.32
- P/E Ratio
- NXT $18.17
- EXAS N/A
- Revenue Growth
- NXT 13.26
- EXAS 12.55
- 52 Week Low
- NXT $30.93
- EXAS $38.81
- 52 Week High
- NXT $71.44
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- NXT 53.52
- EXAS 63.63
- Support Level
- NXT $64.30
- EXAS $46.30
- Resistance Level
- NXT $68.43
- EXAS $56.52
- Average True Range (ATR)
- NXT 2.92
- EXAS 1.67
- MACD
- NXT -0.28
- EXAS 0.91
- Stochastic Oscillator
- NXT 33.61
- EXAS 76.84
About NXT Nextracker Inc.
Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.